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Background. The impact of co-morbid substance use in ﬁrst-episode schizophrenia has not been fully explored.
Method. This naturalistic follow-up of a cohort of 152 people with ﬁrst-episode schizophrenia examined substance
use and clinical outcome in terms of symptoms and social and neuropsychological function.
Results. Data were collected on 85 (56%) of the patient cohort after a median period of 14 months. Over the follow-up
period, the proportion of smokers rose from 60% at baseline to 64%. While 30% reported lifetime problem drinking of
alcohol at baseline, only 15% had problem drinking at follow-up. Furthermore, while at baseline 63% reported lifetime
cannabis use and 32% were currently using the drug, by the follow-up assessment the latter ﬁgure had fallen to 18.5%.
At follow-up, persistent substance users had signiﬁcantly more severe positive and depressive symptoms and greater
overall severity of illness. A report of no lifetime substance use at baseline was associated with greater improvement in
spatial working memory (SWM) at follow-up.
Conclusions. Past substance use may impede recovery of SWM performance in people with schizophrenia in the
year or so following ﬁrst presentation to psychiatric services. The prevalence of substance use other than tobacco
tends to diminish over this period, in the absence of speciﬁc interventions. Persistent substance use in ﬁrst-episode
schizophrenia is associated with more severe positive and depressive symptoms but not negative symptoms, and
should be a target for speciﬁc treatment intervention.
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Introduction
Substance use in people with established schizo-
phrenia is most likely to involve alcohol and cannabis
(Condren et al. 2001; Duke et al. 2001), and this proﬁle
is also seen in ﬁrst-episode patients (Green et al. 2004;
Barnes et al. 2006; Wade et al. 2006). Even relatively
low levels of such co-morbid substance use are asso-
ciated with a poorer outcome, including greater risk of
relapse and a worse response to ﬁrst-generation anti-
psychotic medication (Drake & Brunette, 1998; Hunt
et al. 2002; Kavanagh et al. 2004). This seems to hold
true for ﬁrst-episode patients, even in the short term
(Caspari, 1999; Sorbara et al. 2003). The potential im-
pact on cognitive function is less clear. As McCleery
et al. (2006) point out, while substance use in the
general population can have a negative impact on
cognitive function, studies of early schizophrenia have
generally failed to ﬁnd any relationship between sub-
stance use and neuropsychological functioning (Sevy
et al. 2001; Pencer & Addington, 2003). More generally,
it has been claimed that people with schizophrenia
and substance use would have better social and cog-
nitive functioning than those who are abstinent,
greater resources of this kind being necessary to obtain
substances and maintain substance use (Salyers &
Mueser, 2001; Sevy et al. 2001). Clinical studies ad-
dressing this association have yielded contradictory
ﬁndings (Potvin et al. 2005; Barnes et al. 2006;
McCleery et al. 2006).
The current study assessed substance use and to-
bacco use in ﬁrst-episode schizophrenia at initial
presentation to psychiatric services, and at follow-up.
The aims of the study were:
(1) to ascertain the proportion of patients stopping,
starting or continuing substance use and daily to-
bacco use subsequent to their initial presentation
to psychiatric services with schizophrenia;
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ORIGINAL ARTICLE(2) to examine whether those with and without a
history of substance use at baseline diﬀered sig-
niﬁcantly in any aspects of clinical outcome, speci-
ﬁcally symptoms and cognitive function, in the
ﬁrst year or so of treatment;
(3) to assess the impact of continued substance use on
clinical response to treatment, neuropsychological
performance and social function.
Method
Subjects
Subjects for this epidemiologically-based study were
recruited as part of a prospective, longitudinal study
of ﬁrst-episode schizophrenia in West London. We
have previously provided details of the design and
entry criteria (Hutton et al. 1998). The patients eligible
for this study were aged between 16 and 50 years, and
most were seen at the time of their ﬁrst admission
to hospital. For each patient, a diagnosis of DSM-IV
schizophrenia or schizophreniform disorder was con-
ﬁrmed at diagnostic review by two senior clinicians
(E.M.J., T.R.E.B.).
Assessments
Reports of current alcohol and non-alcohol substance
use were recorded using the Substance Use Rating
Scale, patient version (SURSp; Duke et al. 1994, 2001),
at baseline and follow-up. This scale initially elicits in-
formation about the use of legal drugs such as caﬀeine
and nicotine, and identiﬁes problem and dependent
alcohol use. It then moves on to detailed questioning
about the nature of current (within the past month)
and previous substance use.
Mental state was assessed at both time points as
follows. The Scales for the Assessment of Positive and
Negative Symptoms (SAPS and SANS; Andreasen,
1990)wereusedtoobtainpositive,disorganizationand
negative syndrome scores (Liddle & Barnes, 1990)
for each patient. The Comprehensive Psychopatho-
logical Rating Scale (CPRS; Asberg et al. 1978) was
also administered, from which a score for the 10-
item Montgomery–Asberg Depression Rating Scale
(MADRS; Montgomery & Asberg, 1979) was ex-
tracted. Severity of illness was assessed using the
Clinician Global Impression scale (CGI).
Social function was assessed using the Social Func-
tion Scale (SFS; Birchwood et al. 1990) at both time
points. Individuals are asked about their abilities in
seven areas of social function: activation-engagement,
interpersonal communication, frequency of activities
of daily living, competence at activities of daily
living, participation in social activities, participation
in recreational activities, and employment or occu-
pational activity.
The Schedule for the Assessment of Insight (SAI;
David, 1990) was used at baseline to assess three di-
mensions of insight: awareness of illness, the ability to
correctly attribute psychotic experiences, and the need
for treatment.
Movement disorders were assessed at both base-
line and follow-up, using three rating scales. The
Abnormal Involuntary Movements Scale (AIMS; Guy,
1976) was used to determine the presence of mild
dyskinesia (rating of ‘mild’ in at least one body area),
and tardive dyskinesia using Research Diagnostic
Criteria (RDC): the presence of at least a ‘moderate’
rating in one or more body areas, or ‘mild’ movements
in two or more body areas (Schooler & Kane, 1982).
The Extrapyramidal Side Eﬀects Rating Scale (EPSE;
Simpson & Angus, 1970) was used to diagnose par-
kinsonism, the presence of the condition being deﬁned
as a total scale score of 3 or more. The Barnes Akathisia
Rating Scale (BARS; Barnes, 1989) was used to identify
akathisia, the criterion for the presence of the con-
dition being a score of 2 or more on the global item.
Pre-morbid IQ was estimated with the National
Adult Reading Test Revised (Nelson & Willison, 1991)
at baseline. At baseline and follow-up, measures of
recognition memory, spatial span, spatial working
memory, Tower of London planning and attentional
set shifting were obtained using the Cambridge Auto-
mated Neuropsychological Test Battery (CANTAB;
Sahakian & Owen, 1992), run on an IBM-compatible
PC with a touch-sensitive screen. We have previously
described the nature of these tests, the performance
measures used and the derivation of the test scores in
our patients (Hutton et al. 1998).
Detailed information on the medication regimen
during the follow-up period was obtained from the
patients and their clinical notes. This methodology has
been described previously (Kapasi et al. 2004). Patients
were divided into those prescribed second-generation
(n=33) or ﬁrst-generation (n=20) antipsychotics
throughout the follow-up period and those whose
medication had been inconsistent for various reasons
(n=29), such as switching from one type of anti-
psychotic to another or receiving a combination.
Statistical methods
Data were analysed using SPSS version 14 (SPSS Inc.,
Chicago, IL, USA). Comparisons between groups on
each of the measures were conducted using separate
analyses of variance (ANOVAs) with appropriate post
hoc tests, t tests or x
2 tests as indicated.
Results
Alcohol and drug use data were obtained at 1 year on
85 (56%) of the original 152 patients (Barnes et al. 2006)
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follow-up period was 14 months (range 5–102). Sixty-
seven patients of the original cohort had missing data
regarding the presence of substance use at follow-up
due to being uncontactable (n=20), deceased (n=3)
or refusing further study involvement (n=44). The
85 follow-up subjects did not diﬀer signiﬁcantly from
the 67 subjects lost to follow-up on baseline variables
of age at ﬁrst presentation to services with schizo-
phrenia, gender, history of substance use, syndrome
scores, depression rating, severity of illness or social
function (see Table 1, range of t values: x1.71 to 1.68;
range of x
2 values: 0.32–2.71). In the subgroup of
subjects with insight scores available, those lost to
follow-up had a signiﬁcantly lower mean SAI score at
baseline (t=x2.40, df=88, p=0.018).
Substance use and clinical outcome
Within the follow-up sample, those subjects with
and without a report of lifetime substance use (drugs
and/or alcohol but not including tobacco use) at
baseline were compared with respect to: age at base-
line testing, gender, mental state variables, movement
disorder and social function (see Table 1). The only
signiﬁcant diﬀerence revealed was that the patients
with a history of substance abuse had a signiﬁcantly
higher mean CGI score, indicating a more severe ill-
ness. Repeating the analyses, comparing those with
and without a report of non-alcohol drug use only,
revealed similar results, with those patients reporting
a history of drug use without alcohol problems dem-
onstrating signiﬁcantly higher CGI scores (t=x3.00,
df=75, p=0.004).
To examine change in symptoms and social func-
tion over time in these two groups, repeated measures
ANOVAs were performed with factors of time (base-
line and follow-up) and group (subjects with and
without a report of any lifetime substance use at
baseline). Both groups improved signiﬁcantly over
time on MADRS, CGI and the three schizophrenia
syndrome scores (range of F values: 31.78–113.19).
There was a signiﬁcant group eﬀect for CGI
[F(1,71)=6.37, p=0.014], demonstrating that those
Table 1. Comparison of study subgroups and those lost to follow-up on baseline demographic and clinical variables
Lost to
follow-up
(n=67)
Study follow-up sample (n=85)
No history of
substance use
(n=22)
History of
substance
use (n=63)
Comparison of those
with and without
a history of substance
use at baseline (t/x
2)
Age at testing in years, mean (S.D.) 25.89 (7.28) 27.60 (10.49) 23.89 (6.54) 1.55
Gender: M/F 48/19 14/8 48/15 1.3
Pre-morbid IQ, mean (S.D.) 98.73 (10.40) 99.32 (8.95) 100.06 (10.95) x0.26
Mental state, mean (S.D.)
Symptom-based syndrome scores
Negative syndrome 0.41 (0.25) 0.39 (0.29) 0.43 (0.26) x0.69
Positive syndrome 0.75 (0.49) 0.58 (0.26) 0.67 (0.25) x1.30
Disorganization syndrome 0.39 (0.29) 0.39 (0.30) 0.45 (0.29) x0.77
CGI severity score 4.73 (1.16) 3.90 (1.17) 4.80 (1.12) x3.08*
Depression: MADRS score 17.21 (9.55) 17.32 (8.99) 18.72 (10.74) x0.54
Social function, mean (S.D.)
Social Function Scale score 110.60 (12.05) 114.60 (10.66) 110.57 (12.03) 1.37
Movement disorder, n (%)
Presence of parkinsonism: EPSE criterion 17 (28) 4 (18) 12 (19) 0
Presence of akathisia: BARS criterion 12 (20) 3 (14) 12 (19) 0.27
Presence of tardive dyskinesia
AIMS: mild dyskinesia criteria 6 (10) 3 (14) 13 (21) 0.41
AIMS: RDC 4 (7) 2 (9) 8 (13) 0.15
S.D., Standard deviation; M, male; F, female; IQ, intelligence quotient; CGI, Clinician Global Impression scale; MADRS,
Montgomery–Asberg Depression Rating Scale; EPSE, Extrapyramidal Side Eﬀects Rating Scale; BARS, Barnes Akathisia Rating
Scale; AIMS, Abnormal Involuntary Movements Scale; RDC, Research Diagnostic Criteria.
*p<0.05.
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more ill. There were no main eﬀects of group for any
other clinical measures; the highest F was for the
positive syndrome scores [F(1,83)=1.63, N.S.]. SFS
showed no signiﬁcant improvement over time in
either group. There were no signiﬁcant eﬀects of
grouprtime. Limiting the analysis to those with or
without a lifetime history of non-alcohol substance use
did not alter the results.
To further examine the association between sub-
stance use and clinical outcome, the follow-up sample
was divided into four groups: the 23 subjects report-
ing no substance use at any time (‘persistent non-
users’); the 21 subjects reporting lifetime use at base-
line and current use at follow-up (‘persistent users’);
the 36 subjects reporting lifetime use at baseline but no
report of current use at follow-up (‘baseline only
users’); and the two subjects reporting no substance
use at baseline but current use at follow-up. Given the
small number of patients in the last group, this was
excluded from further analysis. Table 2 provides de-
tails of clinical variables for the three groups (non-
users, persistent users and baseline only users) at
follow-up. The information in the table shows that at
follow-up the persistent users had signiﬁcantly higher
scores for the positive syndrome, overall severity of
illness (CGI) and depressive features (MADRS).
To examine change in symptoms and social func-
tion over time in these three subgroups, repeated
measures ANOVAs were again performed with fac-
tors of time (baseline and follow-up) and group (non-
users, persistent users and baseline only users).
Initially, each of the symptom-based syndromes was
examined separately. The main eﬀects of time revealed
signiﬁcant improvement in negative [F(1,77)=32.30,
p<0.001], positive [F(1,77)=80.50, p<0.001] and dis-
organization [F(1,77)=66.71, p<0.001] syndrome
scores. There were no main eﬀects of group for nega-
tive [F(2,77)=0.64, N.S.] or disorganization syndrome
scores [F(2,77)=0.88], but there was a trend for the
groups to diﬀer with respect to positive syndrome
scores [F(2,77)=2.66, p=0.076]. Similarly, groupr
time interaction eﬀects were not signiﬁcant for
negative [F(2,77)=0.88, N.S.] and disorganization
[F(2,77)=0.64, N.S.] syndromes, but positive syndrome
scores changed diﬀerently over time across the groups
[F(2,77)=5.50, p<0.006]. Least signiﬁcant diﬀerence
(LSD) post hoc analyses showed that the persistent
users improved less than the baseline only users
(p<0.05). Figure 1 displays the positive syndrome
(hallucinations and delusions) scores at baseline and
follow-up for the three substance use subgroups.
The same analysis was then performed on the re-
maining clinical variables. The main eﬀects of time
Table 2. Comparison of follow-up clinical variables for the three substance use subgroups
Main substance use follow-up subgroups
F/x
2
Persistent non-users
(n=23)
Persistent users
(n=21)
Baseline only users
(n=36)
Mental state, mean (S.D.)
Symptom-derived syndrome score
Negative syndrome 0.17 (0.24) 0.29 (0.29) 0.21 (0.24) 1.165
Positive syndrome 0.19 (0.28) 0.40 (0.37) 0.17 (0.24) 4.200*
Disorganization syndrome 0.05 (0.21) 0.15 (0.25) 0.05 (0.15) 1.912
CGI severity score 1.30 (1.21) 2.59 (2.02) 1.32 (1.10) 5.216*
Depression: MADRS score 4.78 (6.60) 10.45 (11.26) 5.11 (7.23) 3.248*
Social function, mean (S.D.)
SFS score 114.05 (11.08) 111.40 (11.95) 116.75 (9.19) 1.458
Insight, mean (S.D.)
SAI score 13.22 (5.89) 11.60 (5.10) 12.40 (4.58) 0.247
Presence of movement disorder, n (%)
Parkinsonism: EPSE criteria 2 (10) 1 (6) 3 (10) 0.192
Akathisia: BARS criteria 3 (14) 3 (14) 2 (6) 1.240
AIMS: mild dyskinesia criteria 2 (10) 2 (11) 4 (12) 0.070
AIMS: RDC 2 (10) 2 (11) 5 (15) 0.453
CGI, Clinician Global Impression scale; MADRS, Montgomery–Asberg Depression Rating Scale; SFS, Social Function Scale;
SAI, Schedule for Assessment of Insight; EPSE, Extrapyramidal Side Eﬀects Rating Scale; BARS, Barnes Akathisia Rating
Scale; AIMS, Abnormal Involuntary Movements Scale; RDC, Research Diagnostic Criteria.
*p<0.05.
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scores [F(1,71)=52.92, p<0.001] and the CGI
[F(1,65)=121.55, p<0.001] but not SFS [F(1,74)=0.30,
N.S.]. There was no main eﬀect of group on the MADRS
[F(2,71)=0.70, N.S.] or SFS [F(2,74)=0.71, N.S.]. There
was a signiﬁcant group eﬀect for CGI [F(2,65)=6.29,
p<0.003], with persistent non-users having signiﬁ-
cantly less severe illness at baseline and follow-up
than either persistent users or baseline only users.
There were no grouprtime eﬀects: the highest F was
for the SFS score [F(2,74)=2.00, N.S.].
An analysis of substance use proﬁle and type
of medication prescribed revealed no diﬀerences in
the proportion of patients in each of the subgroups
who had received purely ﬁrst- or second-generation
antipsychotics or a mixture of the two (x
2=0.60, df=4,
N.S.).
Substance use and cognitive function
The following variables were used to analyse cognitive
function: pre-morbid IQ, spatial span; spatial working
memory errors; Tower of London perfect solutions
planning score; stage reached on the attentional set
shifting task; pattern recognition memory number
correct. No signiﬁcant diﬀerences were found between
patient groups with and without a history of substance
use at baseline (range of t values for all measures was
x0.85 to 0.81). To examine change in cognitive func-
tion over time in these two groups, repeated measures
ANOVAswereperformed.Analysisofthemaineﬀects
of time revealed signiﬁcant improvement in spatial
working memory [F(1,67)=9.63, p=0.003] and spatial
span [F(1,65)=5.64, p=0.02], with a trend for im-
provement in planning [F(1,63)=2.85, p=0.07]. By
contrast, main eﬀects of time were not signiﬁcant for
recognition memory [F(1,63)=0.64, N.S.] or stage
reached on attentional set shifting [F(1,61)=1.89, N.S.].
There were no main eﬀects of group for any of the
measures (highest F was for the pattern recognition
memory task [F(1,63)=1.09, N.S.]. Similarly, there
were no signiﬁcant eﬀects of grouprtime for spatial
span [F(1,65)=0.10, N.S.], recognition memory score
[F(1,63)=0.24, N.S.], attentional set shifting stage
reached [F(1,61)=0.31, N.S.] or planning [F(1,63)=
0.39, N.S.]. However, there was a signiﬁcant interaction
for spatial working memory errors [F(1,67)=4.61,
p=0.04] due to the group reporting no drug use at
baseline showing a signiﬁcant improvement [mean
reduction in errors: 11.09 (S.E.=4.02); F(1,67)=11.01,
p=0.001] over the follow-up period, which was not
found in the group reporting substance abuse [mean
reduction in errors: 2.02 (S.E.=2.75); F(1,67)<1, N.S.].
Repeating the analysis with only those subjects with
or without a lifetime history of non-alcohol substance
use at baseline revealed essentially similar ﬁndings.
Further analysis comparing spatial working memory
performance and pattern of substance use over the
follow-up period in subgroups such as persistent
users and baseline only users was precluded by the
small numbers.
Use of substances over the follow-up period
Data on the full range of substance use at both baseline
and follow-up were available for 81 of the follow-up
sample.
Smoking
At ﬁrst assessment, 49 (60%) of the sample were
smokers, and this ﬁgure had risen to 52 (64%) at fol-
low-up. Only eight out of the 49 smoking at baseline
had stopped smoking, while 11 of the 32 non-smokers
at baseline had started smoking over the follow-up
period. Further analysis investigating the eﬀects of
tobacco alone on clinical and neuropsychological fac-
tors was omitted because at baseline all but nine of the
49 smokers used other substances.
Alcohol use
At baseline, 24 (30%) of the subjects reported problem
drinking, of whom 16 had evidence of dependent
drinking. By the follow-up assessment, only seven
of these 24 subjects still had a drinking problem,
although there was evidence of dependent drinking
in all but one. An additional ﬁve subjects had devel-
oped a drinking problem during the follow-up period,
so that the total number with such a problem at the
time of follow-up was 12 (15%).
Cannabis
At baseline, 51 (63%) subjects reported lifetime can-
nabis use, and 26 (32%) reported current use at that
time. At follow-up, 15 (18.5%) were using the drug,
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subgroups at baseline (%) and follow-up (&): positive
symptom syndrome.
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at the initial assessment.
Stimulants
At baseline, 29 (36%) subjects reported lifetime use
of stimulants (predominantly amphetamine and
cocaine), but only two (2.5%) were using these drugs
at follow-up.
Other substances
The baseline ﬁgures for the lifetime use of other sub-
stances were as follows: ecstasy (3,4-methylenedioxy-
methamphetamine, MDMA) 30 (37%); hallucinogens
(such as lysergic acid diethylamide, LSD) 28 (34.5%);
opiates 9 (11%); barbiturates and/or benzodiazepines
11 (13.5%); phencyclidine (PCP) and/or angel dust 6
(7%); other substances (such as khat) six (7%). At the
timeofthefollow-upassessments,nooneinthesample
reported the use of any of these substances.
Discussion
Reduction in substance use
The ﬁndings suggest that in people with ﬁrst-episode
schizophrenia, a report of past or current co-morbid
substance useat thetime of ﬁrstpresentation toclinical
services is a poor indicator of persistent substance use
following the initiation of treatment. Despite the rela-
tively high proportion of patients in the sample re-
porting a history of problem or dependent drinking
and/or cannabis, stimulant or other drug use when
ﬁrst presenting to psychiatric services, the ﬁgures for
currentuseatfollow-upwererelativelylow.Atfollow-
up, only two people in the sample were using stimu-
lants and there was no reported use of substances such
as ecstasy, hallucinogens, opiates, barbiturates, ben-
zodiazepines or PCP.
With regard to cannabis, the most common, non-
alcohol substance used, there was a marked reduction
in the number of people in the sample reporting
its current use from baseline to the end of a median
follow-up period of more than a year. While nearly a
third (32%) of patients reported current cannabis use
at initial presentation, only 14 (17%) were still using at
follow-up, although one other patient had started
using the drug during that period. These ﬁndings are
in line with those of Caspari (1999), who followed up a
sample of people with schizophrenia of relatively
early onset, with a history of cannabis use at their
index admission. Reassessed more than 5 years later,
nearly half the cases (48%) had discontinued any
substance use. Similarly, in a retrospective study of
ﬁrst-episode psychosis, Lambert et al. (2005) reported
a reduction in prevalence of co-morbid substance use
disorder from 62% at baseline to 36% in those com-
pleting 18 months of treatment in an early intervention
programme. Furthermore, in a prospective study of
ﬁrst-episode psychosis by Wade et al. (2006), there
was a signiﬁcant reduction in substance use over a
15-month follow-up period. Speciﬁcally, the pro-
portion using cannabis fell from 63% to 42%.
The patients in our sample were not exposed to any
treatment programme targeted at substance use. It is
therefore plausible but entirely speculative that the
decline in substance use may be partly attributable
to the non-speciﬁc intervention of antipsychotic
medication. There are several reports suggesting that
antipsychotic drugs, particularly second-generation
drugs such as clozapine, olanzapine, quetiapine
and risperidone (Drake et al. 2000; Smelson et al.
2002; Potvin et al. 2003), may be associated with full
or partial remission of substance use. However, in
the present study, second-generation antipsychotics
showed no advantage in relation to use of substances
at follow-up.
Symptoms and illness severity
For the overall sample, there was no signiﬁcant re-
lationship between lifetime report of substance use at
initial presentation and clinical outcome over the fol-
low-up period, in terms of global severity of illness,
social function or severity of psychotic or depressive
symptoms. This is in line with the ﬁndings of the
study by Lambert et al. (2005): in ﬁrst-episode psy-
chosis, baseline substance use disorder had no sig-
niﬁcant inﬂuence on symptom remission at 18 months’
follow-up. However, the ﬁndings of the present study
conﬁrm that persistent substance use following pres-
entation with ﬁrst-episode schizophrenia can be asso-
ciated with greater symptom severity in respect of
positive symptoms such as hallucinations and delu-
sions and depressive symptoms, but not negative
symptoms (Bu ¨hler et al. 2002; Grech et al. 2005). There
are several possible explanations for this association,
and they are not mutually exclusive: ﬁrst-episode
schizophrenia with continuing co-morbid substance
use may be less responsive to antipsychotic medi-
cation (Green et al. 2004), or substance use could be
exacerbating the positive symptoms (Grech et al. 2005).
In addition, patients with more severe psychotic
illness may be more likely to use substances as self-
medication, to relieve depression or positive symp-
toms, the latter being perhaps less plausible, with little
supportive evidence (Addington & Duchak, 1997;
Spencer et al. 2002). A further possibility is that the
poor clinical outcome in those with persistent co-
morbid substance use reﬂects an association with poor
adherence with treatment. However, in a previous
84 I. Harrison et al.study of patients derived from the West London
ﬁrst-episode schizophrenia cohort, we failed to ﬁnd a
relationship between co-morbid substance use and
adherence to medication (Mutsatsa et al. 2003), and
Sorbara et al. (2003) reported that persistent substance
useafterﬁrstadmissionforpsychosishadadeleterious
impact on clinical outcome independent of medication
adherence.
Cognitive impairment
Although cognitive deﬁcits in association with alcohol
and drug use have been extensively reported, they
have tended not to emerge in studies of co-morbid
substanceuseinschizophrenia.Forexample,Sevyetal.
(2001) failed to ﬁnd an association between lifetime
substance use in ﬁrst-episode patients and cognitive
impairment, and Joyal et al. (2003) found no associ-
ation between co-morbid substance use and neuro-
psychological performance in a sample of men with
established schizophrenia.
We have previously demonstrated that patients
with ﬁrst-episode schizophrenia are impaired on as-
pects of executive function, including SWM (Hutton
et al. 1998; Joyce et al. 2002). In the present study,
we examined the possible interactions between base-
line substance use or no substance use and change
in neurocognitive performance measures over the
follow-up period. The only signiﬁcant interaction
was with SWM: a report of no lifetime substance use
at baseline was associated with a signiﬁcantly greater
improvement in SWM performance (see earlier com-
ments about controlling for baseline performance).
The ﬁndings of a speciﬁc improvement in one sub-
group of patients and on one of several tests mitigates
an explanation of this ﬁnding in terms of ‘practice
eﬀects’. In support of this, our unpublished ﬁndings
of test–retest performance after a 1-year interval in
42 normal control subjects showed no signiﬁcant
changes on the SWM test.
A preferred interpretation of this ﬁnding is that the
eﬀects of past use of substances may delay or other-
wise impede recovery of SWM performance over the
ﬁrst year or so of treatment. Impairment of working
memory may be attributable to several of the sub-
stances reported, either alone or in combination. An
association between chronic alcohol consumption and
deﬁcits on working memory tasks has been found in
both animal (Santin et al. 2000) and human studies
(Ambrose et al. 2001; Weissenborn & Duka, 2003).
With regard to non-alcohol substance use, Block et al.
(2002) concluded that chronic drug use is associated
witharangeofcognitiveimpairments,includingmem-
ory problems, which may fail to show improvement
even after several months of abstinence. Speciﬁcally,
long-term and heavy users of cannabis may experi-
ence subtle neuropsychological deﬁcits in attention
and memory that may or may not persist after pro-
longed abstinence, and that require compensatory
eﬀort, calling upon additional brain regions, when
trying to meet the demands of neuropsychological
tasks (Lundqvist, 2005). Cannabis has been associated
with disruption of working memory in samples of
substance users, but only with long-term use (Fletcher
et al. 1996). There is some evidence that ecstasy
(MDMA) can lead to impaired neuropsychological
performance in young people, which may not be re-
versed by prolonged abstinence (Battachary & Powell,
2001; Morgan et al. 2002), but whether or not working
memory is a core deﬁcit remains unclear (Gouzoulis-
Mayfrank et al. 2000; Rodgers, 2000; Battachary &
Powell, 2001; Morgan et al. 2002), and coincident
cannabis use is an important potential confound in
studies in this area (Rodgers, 2000; Croft et al. 2001).
Finally, impairment on some tests of working memory
has been reported for subjects whose primary drug
of abuse was either amphetamines or heroin (Ornstein
et al. 2000).
Limitations of the study
Perhaps the main limitation of this study is the
relatively low proportion of patients reassessed at
follow-up. This is relevant to the interpretation of the
ﬁndings, in that there may have been some selective
drop-out from the study, generating bias. However, in
defence of the generalizability of the sample, those
subjects successfully followed up could not be dis-
tinguished at baseline from those lost to follow-up on
key clinical variables.
Another potential criticism relates to the reliability
of self-report for assessing substance use. The dis-
advantages of such a method are selective under-
reporting of recent use and particular substances, such
as stimulants and opiates (Magura & Kang, 1996). Key
advantages in the context of the present study were
that it could provide information on drug history,
age of onset and remote use, and identify pattern of
use and dependence, as well as cover drugs, such as
LSD and solvents, that would be diﬃcult to test for
with other methods. There is also evidence for the
validity of self-reported substance use in various
clinical groups, including young multiple drug users
receiving treatment (Martin et al. 1988), out-patients
diagnosed with substance use disorder and bipolar
disorder/post-traumatic stress disorder (Weiss et al.
1998), and a mixed psychiatric and substance use
population (Weaver et al. 2003).
As the majority of participants in this epidemiolo-
gically based study who had a history of substance use
Follow-up of substance use in ﬁrst-episode schizophrenia 85had lifetime use of more than one substance, the data
do not allow for any conclusions regarding the eﬀects
of any particular substance.
Clinical implications
The ﬁndings of the present study add to the evidence
that, for people with ﬁrst-episode schizophrenia, con-
tinued substance use may worsen outcome, and stop-
ping the use of substances, such as cannabis, may be
associated with an improved outcome (Linszen et al.
1994). The ﬁndings also reinforce the argument that
those involved in the care of people with ﬁrst-episode
schizophrenia need to identify substance use disorder
early and develop strategies to limit continued sub-
stance use and prevent the problem developing in
those not currently using (Addington & Addington,
2001; Green et al. 2004). The ﬁndings also suggest
that, at least in an urban, UK sample, a relatively high
proportion of those with both schizophrenia and a re-
port of lifetime substance use at ﬁrst presentation
to services will not be using alcohol or non-alcohol
substances a year or so later, in the absence of any
speciﬁc psychological interventions for substance
use. Therefore, such interventions might be most ef-
fectively targeted on the minority exhibiting persistent
substance use, in whom more severe residual positive
symptoms may be seen.
Although use of most substances declined over the
follow-up period, tobacco use proved to be an excep-
tion. The proportion of patients smoking showed a
slight increase over the follow-up period. Wade et al.
(2006) reported a similar ﬁnding; there was little
change in the proportion of their cohort of patients
with ﬁrst-episode psychosis using tobacco over a 15-
month follow-up period. This area of dependency in
people in the early stages of schizophrenia should be a
priority area for further research on mechanisms and
treatment possibilities.
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